Special Senses & Otolaryngology

Hypertensive retinopathy: grading

Clinical Overview and When to Suspect Hypertensive Retinopathy

— Any patient with stage 2 hypertension (≥140/90 in office, ≥135/85 home) on initial diagnosis, especially if BP duration unknown

— Headache, blurred vision, transient visual obscurations, scotomata with elevated BP

— Suspected hypertensive emergency (BP ≥180/120 with symptoms) — fundoscopy is mandatory at bedside

— Pregnancy with BP elevation: preeclampsia, eclampsia

— Secondary HTN workup: pheochromocytoma, renovascular disease, primary aldosteronism often present with grade III–IV changes

— Diabetic patients (overlap with diabetic retinopathy alters management)

— Keith-Wagener-Barker (KWB) — classic 4-grade system, still the Step 3 favorite

— Modified Scheie — separates HTN changes from arteriosclerotic changes

— Wong-Mitchell — modern 3-tier (mild/moderate/malignant), better correlates with stroke and CV mortality

— Prevalence of any HTN retinopathy in adults with HTN: 2–15%

— Strong predictor of stroke (≈2-3× risk), CHF, CV death — independent of BP level

— Black and South Asian patients carry higher prevalence and severity at same BP

Board pearl: A fundoscopic finding of papilledema in a hypertensive patient = hypertensive emergency regardless of symptom burden — admit, IV antihypertensives, target MAP reduction ≤25% in the first hour. Do not lower BP precipitously; risk of watershed infarct and optic nerve ischemia.

Definition: retinal microvascular changes from chronic or acutely elevated systemic blood pressure, ranging from subtle arteriolar narrowing to florid optic disc edema with hemorrhages and exudates.

Why it matters on Step 3: hypertensive retinopathy is a biomarker of end-organ damage equivalent in prognostic weight to LVH, microalbuminuria, or elevated creatinine — it reclassifies a patient's cardiovascular risk and changes BP targets and urgency of therapy.

When to suspect:

Classification systems used clinically:

Epidemiology pearls:

Presentation Patterns and Key History

— Grade I–II changes are usually incidental on routine ophthalmoscopy or dilated eye exam

— Patient referred from optometrist with note "AV nicking, arteriolar narrowing — recommend BP evaluation"

— Step 3 management: any new fundoscopic HTN finding triggers home BP monitoring, ABPM if available, and assessment for other end-organ damage (ECG, urine albumin/creatinine, BMP)

— Gradual blurred vision, headaches (often occipital, morning), occasional floaters

— Often coincides with poorly controlled chronic HTN

— Headache, nausea/vomiting, vision loss, diplopia, scotomata

— Encephalopathy: confusion, seizures

— Chest pain, dyspnea (concurrent LV failure, aortic dissection)

— Oliguria/hematuria (thrombotic microangiopathy of kidney)

— Duration and control of HTN; adherence to antihypertensives, abrupt clonidine or beta-blocker cessation → rebound

— Medications and substances: cocaine, methamphetamine, MAOI + tyramine, sympathomimetic decongestants, OCPs, NSAIDs, erythropoietin, VEGF inhibitors

— Pregnancy status in any woman of reproductive age — preeclampsia must be excluded

— Symptoms of secondary HTN: episodic flushing/diaphoresis/palpitations (pheo), proximal weakness (aldosteronism), snoring/witnessed apnea (OSA), claudication or abdominal bruit (renovascular)

— Family history of early CV death, stroke, CKD

— Diabetes duration, A1c (overlap with diabetic retinopathy)

— Visual symptoms: sudden monocular loss suggests CRAO/CRVO, not pure HTN retinopathy

— Acute severe BP rise (e.g., pheo crisis, eclampsia) can produce grade IV findings within days without prior chronic changes

— Chronic slow HTN produces predominantly arteriosclerotic changes (copper/silver wiring)

Key distinction: Acute hypertensive retinopathy = flame hemorrhages, cotton-wool spots, disc edema; chronic = AV nicking, wire-like arterioles. Both can coexist.

Asymptomatic presentation (most common):

Symptomatic mild–moderate retinopathy:

Malignant/accelerated retinopathy (grade III–IV):

Key historical elements to elicit:

Time course matters:

Physical Exam Findings (and Hemodynamic Assessment)

— Grade I: mild generalized arteriolar narrowing, increased light reflex (early copper wiring). Asymptomatic. Often missed without dilation.

— Grade II: focal arteriolar narrowing + arteriovenous (AV) nicking (Gunn sign — vein compressed at crossing; Salus sign — vein deflection). Copper-wire arterioles. Reflects sustained chronic HTN.

— Grade III: grade II findings PLUS flame-shaped hemorrhages, cotton-wool spots (nerve fiber infarcts), hard exudates (lipid, sometimes in macular star pattern), microaneurysms. Indicates significant end-organ damage.

— Grade IV (malignant): all of grade III PLUS papilledema (blurred disc margins, elevation, peripapillary hemorrhages, loss of venous pulsations). Defines hypertensive emergency.

— Mild: any of arteriolar narrowing, AV nicking, opacification, or combinations

— Moderate: hemorrhages, microaneurysms, cotton-wool spots, hard exudates

— Malignant: moderate + disc swelling

— BP both arms, postural BP, HR, radial-femoral delay (coarctation)

— Carotid, abdominal, renal bruits (renovascular)

— Cardiac: S4 (LVH), S3 (failure), displaced PMI, murmurs (AI in dissection)

— Lungs: rales (acute pulmonary edema in hypertensive emergency)

— Neurologic: focal deficits, papilledema correlation with HTN encephalopathy

— Skin: café-au-lait (NF1 + pheo), striae/moon facies (Cushing)

— Lower-extremity edema, abdominal palpation for AAA

CCS pearl: In a CCS case of BP 220/130 with headache and blurred vision, "fundoscopic exam" is a high-yield order that uncovers grade IV findings and justifies ICU admission with IV labetalol or nicardipine drip — order it early; it changes disposition.

Fundoscopic landmarks — Keith-Wagener-Barker grading:

Wong-Mitchell simplification (more reproducible):

Technique: direct ophthalmoscope in darkened room; dilate with tropicamide unless contraindicated (suspected angle-closure, neuro exam needed). Document each eye separately.

Hemodynamic and systemic exam:

Diagnostic Workup — Initial Labs and Studies

— BMP/CMP: creatinine, eGFR, electrolytes — hypokalemia + HTN raises aldosteronism suspicion; rising Cr supports thrombotic microangiopathy in malignant HTN

— Urinalysis + urine albumin-to-creatinine ratio (UACR): proteinuria, hematuria, RBC casts (renal end-organ damage; preeclampsia screening if pregnant)

— CBC with peripheral smear: schistocytes + thrombocytopenia + LDH↑ + haptoglobin↓ = hypertensive thrombotic microangiopathy (mimics TTP/HUS, but treat the BP)

— Fasting glucose, A1c, lipid panel for global CV risk

— TSH (thyrotoxicosis can precipitate HTN)

— 12-lead ECG: LVH (Sokolow-Lyon, Cornell), strain pattern, ischemic changes

— Troponin if chest pain or acute severe BP

— NT-proBNP/BNP if dyspnea or volume overload

— CXR: cardiomegaly, pulmonary edema, widened mediastinum (consider dissection)

— CT angiography of chest/abdomen if dissection suspected (tearing chest/back pain, BP differential, widened mediastinum)

— CT head non-contrast for new neuro deficits or severe HTN with altered mental status (rule out ICH, PRES on MRI)

— Same-day for suspected grade IV, vision loss, or diagnostic uncertainty (CRVO/CRAO mimics)

— Within 1–2 weeks for grade III without papilledema

Step 3 management: Document HTN-mediated organ damage (HMOD) explicitly — retina, heart (LVH/HF), kidney (eGFR, UACR), brain, vasculature. Presence of HMOD upgrades risk and tightens BP target to <130/80 per ACC/AHA 2017.

Why work up: confirming retinopathy alone is insufficient — you must (1) quantify other end-organ damage, (2) screen for secondary causes when indicated, (3) risk-stratify for cardiovascular events.

Initial laboratory panel (every patient with grade ≥II or any acute severe HTN):

Cardiac assessment:

Imaging:

Pregnancy testing in all reproductive-age women with new severe HTN — mandatory before pharmacotherapy choices.

Ophthalmologic referral:

Diagnostic Workup — Advanced and Confirmatory Studies

— Dilated fundus exam by ophthalmology with documentation of vessel caliber, AV ratio, hemorrhage distribution

— Fundus photography for serial monitoring

— Optical coherence tomography (OCT): detects macular edema, subretinal fluid, choroidal involvement (Elschnig spots in choroidopathy)

— Fluorescein angiography: delineates non-perfusion areas, leakage; useful when distinguishing from diabetic retinopathy or vein occlusion

— OCT-angiography: emerging non-invasive vascular imaging

— 24-hour ambulatory BP monitoring (ABPM) — gold standard; identifies non-dipping pattern (≥10% nocturnal drop absent) which independently predicts CV events and severe retinopathy

— Home BP monitoring (HBPM) for white-coat and masked HTN

— Onset <30 or >55 years, abrupt onset, resistant HTN (≥3 drugs including diuretic), severe retinopathy out of proportion to BP, hypokalemia, abdominal bruit, episodic symptoms

— Primary aldosteronism: plasma aldosterone-to-renin ratio (off interfering meds)

— Renovascular: renal duplex ultrasound (first-line), CT/MR angiography

— Pheochromocytoma: plasma free metanephrines or 24-hour urinary fractionated metanephrines/catecholamines

— Cushing: late-night salivary cortisol, 1-mg dexamethasone suppression, 24-hr urinary free cortisol

— OSA: polysomnography if symptoms; treat with CPAP

— Coarctation: echo, CT/MRA

— Echocardiogram: quantify LV mass, diastolic function, EF — supports HMOD diagnosis

— Carotid IMT, ABI for atherosclerotic burden in select cases

— MRI brain if encephalopathy: posterior reversible encephalopathy syndrome (PRES) shows parietooccipital vasogenic edema — strongly associated with malignant HTN and eclampsia

Board pearl: A non-dipping nocturnal BP pattern on ABPM in a patient with even mild retinopathy independently predicts stroke; switching at least one antihypertensive to bedtime dosing (chronotherapy) has evidence for risk reduction.

Confirming retinopathy and excluding mimics:

Ambulatory and home BP monitoring:

Secondary HTN workup — pursue when:

Cardiac and vascular structure:

Neuroimaging:

Risk Stratification and First-Line Management Logic

— Grade I–II (mild): outpatient management; same goals as any HTN with HMOD

— Grade III (moderate): urgent outpatient escalation; consider same-day ophtho, prompt initiation/optimization of antihypertensives, BP target <130/80

— Grade IV (malignant retinopathy / hypertensive emergency): inpatient ICU, IV antihypertensives, controlled BP lowering

— Hypertensive urgency: BP ≥180/120 without acute end-organ damage. Oral therapy, outpatient or short observation; lower over 24–48 hours.

— Hypertensive emergency: BP ≥180/120 with acute target-organ damage (retinopathy grade IV, encephalopathy, ACS, dissection, AKI, pulmonary edema, eclampsia). Lower MAP by ≤25% in first hour, then to 160/100 over 2–6 hours, then normalize over 24–48 hours. Exceptions: aortic dissection (SBP <120, HR <60 within 20 min) and ischemic stroke (permissive HTN unless thrombolysis candidate).

— DASH diet, Na <1.5–2.3 g/day, K supplementation via food unless CKD

— Weight loss (≈1 mmHg per kg up to ~10 kg)

— Aerobic + resistance exercise 90–150 min/week

— Alcohol ≤2 drinks/day men, ≤1 women

— Smoking cessation

— Address OSA

— Statin if ASCVD risk ≥10% or established disease — retinopathy is HMOD and supports moderate-intensity statin even at borderline scores

— Aspirin only for secondary prevention or selected primary prevention (not routine)

Step 3 management: A patient with grade III retinopathy and BP 168/104 without acute symptoms = stage 2 HTN with HMOD, outpatient — start two-drug therapy (typically ACEi/ARB + CCB or thiazide-like diuretic) simultaneously, follow-up in 2–4 weeks.

Stratify by retinopathy grade + overall CV risk:

Defining the BP scenario (ACC/AHA framework):

Why slow lowering matters: chronic HTN shifts cerebral autoregulation rightward; rapid reduction risks watershed cerebral, coronary, and optic nerve ischemia.

Lifestyle bundle (always):

Concomitant therapies:

Pharmacotherapy — First-Line Drug Regimen

— ACE inhibitors (lisinopril, ramipril) — preferred with CKD, proteinuria, diabetes, HF, post-MI. Monitor K⁺ and Cr at 1–2 weeks. Cr rise <30% acceptable.

— ARBs (losartan, valsartan) — substitute if cough/angioedema with ACEi

— Calcium channel blockers (amlodipine) — strong in older adults and Black patients

— Thiazide-like diuretics (chlorthalidone, indapamide preferred over HCTZ for CV outcomes)

— Black patients without CKD: CCB or thiazide first; add ACEi/ARB later

— CKD with albuminuria: ACEi or ARB first; add SGLT2 inhibitor for renal protection if diabetic or CKD with proteinuria

— HFrEF: ACEi/ARB or ARNI, beta-blocker, MRA, SGLT2i

— Post-MI/angina: beta-blocker + ACEi/ARB

— Add spironolactone (PATHWAY-2) — fourth-line drug of choice

— Confirm adherence, exclude white-coat, screen for secondary causes

— Labetalol IV bolus or infusion — broad utility; avoid in severe bradycardia, asthma, decompensated HF

— Nicardipine or clevidipine infusion — easy titration; nicardipine avoided in HF

— Nitroprusside — fast, but cyanide/thiocyanate toxicity especially in renal/hepatic disease; limit duration

— Esmolol — preferred in dissection (rapid HR control)

— Hydralazine — preferred in preeclampsia/eclampsia along with IV labetalol or oral nifedipine

— Phentolamine — for catecholamine excess (pheo, cocaine, MAOI crisis); never start beta-blocker first in pheo (unopposed alpha → worse HTN)

— Fenoldopam — useful in AKI

Board pearl: Cocaine-induced hypertensive emergency → benzodiazepines first, then phentolamine or nicardipine; avoid pure beta-blockers due to unopposed alpha vasoconstriction. Labetalol is acceptable per most US guidance but tested cautiously.

Chronic HTN with retinopathy (outpatient): target <130/80 mmHg (ACC/AHA 2017 with HMOD).

First-line agents (any of four, combine two for stage 2):

Specific populations:

Resistant HTN (BP uncontrolled on 3 drugs including a diuretic):

Acute hypertensive emergency (grade IV retinopathy, IV drugs):

Expanded Pharmacology and Disease-Specific Strategies

— Diabetes + albuminuria: ACEi or ARB + SGLT2 inhibitor (empagliflozin, dapagliflozin); add finerenone if persistent albuminuria with eGFR ≥25

— HFrEF: ARNI (sacubitril-valsartan) > ACEi/ARB; carvedilol/metoprolol succinate/bisoprolol; spironolactone; SGLT2i

— HFpEF: SGLT2i (empagliflozin/dapagliflozin) + diuretic + treat HTN aggressively

— CAD/angina: beta-blocker + ACEi/ARB; long-acting nitrate or CCB for symptoms

— AF + HTN: beta-blocker or non-DHP CCB (diltiazem/verapamil) for rate; anticoagulate per CHA₂DS₂-VASc

— Migraine: beta-blocker (propranolol) or candesartan

— BPH: alpha-blocker (doxazosin) as add-on — not monotherapy (ALLHAT: increased HF)

— Pregnancy: labetalol, nifedipine ER, methyldopa, hydralazine; avoid ACEi/ARB/renin inhibitors/spironolactone

— NSAIDs raise BP, blunt diuretic/ACEi effect, worsen CKD

— Decongestants (pseudoephedrine, phenylephrine)

— OCPs in women with HTN/migraine with aura/smoking >35

— Stimulants (ADHD meds, cocaine, meth)

— VEGF inhibitors (bevacizumab) — paradoxically can both raise BP and treat HTN-related macular edema

— Single-pill combinations (ACEi + CCB, ACEi + thiazide, ARB + amlodipine + HCTZ) improve adherence and BP control

— Once-daily dosing preferred; consider bedtime dosing of one agent for non-dippers

— No specific eye drug for HTN retinopathy itself — BP control reverses or stabilizes most grade I–III findings within weeks to months

— Anti-VEGF (ranibizumab, aflibercept) or focal laser for HTN-associated macular edema or neovascularization

— Treat coexisting diabetic retinopathy per standard ADA/AAO pathways

Step 3 management: A diabetic with grade III hypertensive retinopathy and UACR 600 mg/g — initiate ACEi (or ARB) + amlodipine + SGLT2 inhibitor; target BP <130/80, A1c <7%, and add statin. Refer to ophthalmology within 1 week.

Drug selection by comorbidity (compelling indications):

Drugs to avoid or use cautiously:

Adherence and combination pills:

Ocular-directed therapy:

Special Populations — Elderly and Renal/Hepatic Impairment

— SBP target <130 mmHg per ACC/AHA if tolerated (SPRINT extension to ≥75 supports benefit)

— In frail elderly, institutionalized, or limited life expectancy, individualize to <140/90 to avoid orthostatic injury and falls

— Check orthostatic vitals before and after dose escalation

— Prefer amlodipine, ACEi/ARB, chlorthalidone (low dose); avoid alpha-blockers as monotherapy (orthostasis), avoid central agents (clonidine — sedation, rebound), minimize anticholinergic burden

— Beers criteria: avoid short-acting nifedipine, clonidine first-line; caution with non-selective beta-blockers

— Polypharmacy review at every visit

— eGFR <60 or albuminuria >30 mg/g: target <130/80; ACEi or ARB foundational

— Tolerate Cr rise ≤30% and K⁺ ≤5.5 after ACEi/ARB start; if K⁺ rises, add loop diuretic, low-K diet, or patiromer rather than abandoning the drug

— eGFR <30: thiazides less effective — switch to loop diuretic (furosemide bid, torsemide). Chlorthalidone has some evidence at low eGFR (CLICK trial) but caution.

— Avoid spironolactone if eGFR <30 or K⁺ >5; consider finerenone for diabetic CKD

— Dose-adjust atenolol, lisinopril, hydrochlorothiazide

— Pre-dialysis BP <140/90, post-dialysis <130/80 (targets vary)

— Avoid agents removed by dialysis without redosing (atenolol, lisinopril) — prefer amlodipine, carvedilol, irbesartan

— Labetalol, methyldopa can cause hepatotoxicity — avoid in active liver disease

— Nitroprusside accumulates thiocyanate in liver failure

— Prefer nicardipine, clevidipine for hypertensive emergency in cirrhosis

— Spironolactone often beneficial in cirrhotic ascites

Key distinction: Treat retinopathy-stage HMOD aggressively in elderly but monitor for orthostasis and AKI; isolated systolic HTN with wide pulse pressure (≥60) reflects arterial stiffness and is a high-yield elderly pattern that still warrants treatment.

Older adults (≥65, ambulatory, community-dwelling):

CKD:

Dialysis patients:

Hepatic impairment:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Hypertensive retinopathy in pregnancy = preeclampsia/eclampsia until proven otherwise; check BP, urine protein, platelets, LFTs, Cr, LDH (HELLP)

— Severe features: BP ≥160/110, plt <100k, AST/ALT 2× normal, Cr >1.1, pulmonary edema, visual symptoms or scotomata, severe headache

— Acute BP control: IV labetalol, IV hydralazine, oral immediate-release nifedipine

— Magnesium sulfate for seizure prophylaxis in preeclampsia with severe features and eclampsia

— Definitive treatment = delivery at appropriate gestational age (≥37 wk for preeclampsia without severe features; ≥34 wk with severe features)

— Chronic HTN in pregnancy: target <140/90 (CHAP trial); labetalol, nifedipine ER, methyldopa; AVOID ACEi/ARB/aliskiren/spironolactone (teratogenic — renal dysgenesis, oligohydramnios)

— Retinal findings (serous retinal detachment, Elschnig spots, cotton-wool spots) usually resolve postpartum

— BP check at 3–7 days, 1–2 weeks; continue antihypertensives as needed

— Lifetime ASCVD risk doubles after preeclampsia — counsel and screen

— HTN defined by age/sex/height-percentile tables; ≥95th percentile = stage 1, ≥95th + 12 or ≥140/90 = stage 2

— Retinopathy in children is rare — strongly suggests secondary HTN: renal parenchymal disease, renovascular (FMD), coarctation, pheochromocytoma, endocrine (Cushing, hyperthyroid)

— Workup: renal US with Doppler, plasma renin/aldosterone, metanephrines, echo

— First-line drugs: ACEi, ARB, CCB, thiazide; avoid ACEi/ARB in sexually active adolescent girls without contraception counseling

— Screen for anabolic steroid, stimulant, energy drink use

— Avoid non-selective beta-blockers (impair performance, asthma)

— Calcineurin inhibitors (tacrolimus, cyclosporine) cause HTN; prefer CCBs (amlodipine; but watch tacro level interactions with diltiazem/verapamil)

Board pearl: New-onset HTN with retinopathy in a child or young adult = secondary HTN workup is mandatory, not optional.

Pregnancy and preeclampsia:

Postpartum follow-up:

Pediatrics:

Athletes and adolescents:

Transplant recipients:

Complications and Adverse Outcomes

— Hypertensive choroidopathy: young patients with acute severe HTN (eclampsia, pheo) — Elschnig spots (focal RPE infarcts), Siegrist streaks (linear hyperpigmentation along choroidal arteries), exudative retinal detachment

— Hypertensive optic neuropathy: disc edema, optic atrophy, permanent visual field loss

— Branch/central retinal vein occlusion (BRVO/CRVO): HTN is leading systemic risk factor — sudden painless vision loss, "blood and thunder" fundus

— Branch/central retinal artery occlusion (BRAO/CRAO): pale retina with cherry-red spot — embolic, but HTN/atherosclerosis underlying

— Macular edema, epiretinal membrane

— Ischemic optic neuropathy (NAION)

— Vitreous hemorrhage from neovascularization in severe cases

— Stroke (ischemic and hemorrhagic) — risk roughly doubles with moderate retinopathy

— CHF — LVH progresses to diastolic and systolic dysfunction

— Acute aortic dissection — sudden tearing chest/back pain, BP differential

— Hypertensive nephrosclerosis — slow CKD progression with bland sediment

— Malignant nephrosclerosis — AKI, thrombotic microangiopathy, "onion-skin" arteriolar lesions

— Hypertensive encephalopathy / PRES — headache, seizures, cortical blindness, posterior white matter edema

— MI, atrial fibrillation, sudden cardiac death

— Overshoot hypotension → watershed cerebral infarction, optic nerve infarction, AKI

— AKI / hyperkalemia on ACEi/ARB

— Angioedema (ACEi — higher in Black patients; switch to ARB cautiously, monitor)

— Hypokalemia on thiazides

— Cyanide toxicity with prolonged nitroprusside (metabolic acidosis, elevated lactate, altered mental status — treat with hydroxocobalamin)

CCS pearl: Patient on nitroprusside drip >24–48 hours with rising lactate and confusion = cyanide toxicity — stop drug, give hydroxocobalamin or sodium thiosulfate, switch to nicardipine.

Ocular complications:

Systemic complications signaled by retinopathy severity:

Treatment-related complications:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Hypertensive emergency: grade IV retinopathy with papilledema, encephalopathy, acute pulmonary edema, ACS, dissection, eclampsia, AKI from malignant HTN, intracranial hemorrhage

— Need for IV continuous antihypertensive infusion with arterial line monitoring

— Hemodynamic instability or end-organ ischemia requiring titrated therapy

— Hypertensive urgency without acute organ damage but BP ≥180/120 refractory to oral agents

— Newly diagnosed grade III retinopathy needing rapid drug titration and observation

— Grade I–II retinopathy with stage 1–2 HTN

— Asymptomatic with controllable BP and reliable follow-up

— Ophthalmology: same-day if grade IV, vision loss, suspected CRVO/CRAO, or diagnostic uncertainty; routine within 1–2 weeks otherwise

— Nephrology: AKI, eGFR <30, refractory HTN, suspected renovascular disease, thrombotic microangiopathy

— Cardiology: ACS, dissection, HF, refractory or secondary HTN evaluation

— Endocrinology: confirmed pheochromocytoma, aldosteronism, Cushing

— Neurology: stroke, encephalopathy, PRES

— OB/MFM: any pregnant patient with HTN and retinopathy — immediate consult, consider delivery planning

— Vascular surgery / IR: renal artery stenosis, dissection

— Genetic counseling: suspected NF1, MEN2, von Hippel-Lindau (pheo)

— Order: vitals q15min, IV access ×2, arterial line, continuous ECG/SpO₂, labetalol or nicardipine drip, urgent labs (CMP, CBC, troponin, BNP, UA), ECG, CXR, fundoscopy, urine pregnancy if applicable, ICU admission

— Then: titrate to MAP reduction ≤25% in 1st hour; reassess neuro and renal q1–2h; transition to oral agents when stable over 8–24h

— Discharge with two-drug oral regimen, ophthalmology follow-up, primary care in 1 week

Step 3 management: Always document end-organ damage in admission note — drives admission level, billing, and downstream guideline-directed therapy.

ICU admission criteria:

Step-down or telemetry floor:

Outpatient with close follow-up:

Consult triggers:

CCS sequence for hypertensive emergency with grade IV retinopathy:

Key Differentials — Same-Category (Other Retinopathies and Optic Disc Pathologies)

— Microaneurysms, dot-and-blot hemorrhages, hard exudates, neovascularization in proliferative disease

— Distribution favors posterior pole; HTN hemorrhages are more flame-shaped (nerve fiber layer) and peripheral

— Frequently coexists with HTN retinopathy; dual disease worsens prognosis

— Screen all diabetics with annual dilated exam (or every 2 years if no retinopathy and well-controlled per ADA)

— Sudden painless monocular vision loss, "blood and thunder" fundus (diffuse hemorrhages, dilated tortuous veins, disc edema)

— HTN is biggest risk factor; workup includes HTN, glaucoma, hypercoagulability if young

— Sudden painless vision loss, pale retina with cherry-red spot at fovea, "boxcarring" of arterioles

— Embolic — workup carotid Doppler, echo, ECG for AF; consider GCA if >50

— Carotid stenosis >90%, mid-peripheral hemorrhages, dilated but not tortuous veins, neovascularization

— History of head/neck or ocular RT; microaneurysms, telangiectasias, cotton-wool spots — looks like diabetic/HTN retinopathy

— Papilledema from raised ICP: bilateral, normal vision early, headache worse supine, transient visual obscurations; LP reveals high opening pressure

— Hypertensive disc edema: extremely high BP, hemorrhages elsewhere, systemic features

— Painful monocular vision loss, RAPD, color desaturation; MS workup

— Arteritic (GCA): age >50, jaw claudication, ESR/CRP elevated — emergency high-dose steroids

— Non-arteritic: "disc at risk," nocturnal hypotension, sleep apnea

Key distinction: Bilateral disc edema with severe HTN = grade IV hypertensive retinopathy; bilateral disc edema with normal BP and headache = papilledema from raised ICP — order MRI/MRV and LP, not antihypertensives.

Diabetic retinopathy:

Central or branch retinal vein occlusion (CRVO/BRVO):

Retinal artery occlusion (CRAO/BRAO):

Ocular ischemic syndrome:

Radiation retinopathy:

Papilledema vs hypertensive disc edema:

Optic neuritis:

Anterior ischemic optic neuropathy (AION):

Key Differentials — Other-Category Causes of Retinal/Optic Findings

— TTP: ADAMTS13 <10%, pentad (MAHA, thrombocytopenia, neuro, fever, renal); fundus may show hemorrhages — but BP often normal

— HUS / aHUS: diarrhea-associated (STEC) or complement-mediated; AKI prominent

— Scleroderma renal crisis: new severe HTN, retinopathy, AKI, MAHA in scleroderma — emergency ACE inhibitor (captopril) is the answer; do not withhold ACEi here

— APLA / catastrophic APS: thrombi in multiple beds

— GCA: AION, jaw claudication, scalp tenderness — start high-dose steroids before biopsy

— GPA, EGPA, PAN: retinal vasculitis, renal/lung involvement

— Susac syndrome: young women, encephalopathy + branch retinal artery occlusions + sensorineural hearing loss

— CMV retinitis: HIV CD4 <50 — "pizza pie" hemorrhages with necrosis; ganciclovir

— HIV retinopathy: cotton-wool spots without infection, asymptomatic

— Syphilis, tuberculosis, toxoplasmosis uveitis/chorioretinitis

— Endocarditis: Roth spots (white-centered hemorrhages) — also seen in leukemia, anemia, SLE

— Leukemia, severe anemia, polycythemia, hyperviscosity (Waldenström, myeloma): hemorrhages, venous dilation, Roth spots

— Pheochromocytoma crisis: paroxysmal HTN with retinopathy — plasma metanephrines, then alpha-blockade before beta-blockade before surgery

— Thyrotoxicosis, Cushing

— Cocaine, methamphetamine, MAOI + tyramine, sympathomimetics, abrupt clonidine withdrawal

— VEGF inhibitor systemic therapy: HTN, proteinuria

— Tacrolimus/cyclosporine: PRES, HTN

— PRES: posterior white matter edema on MRI in HTN, eclampsia, immunosuppressants

— RCVS: thunderclap headache, reversible vasoconstriction

Board pearl: In scleroderma renal crisis, ACE inhibitor (captopril) is the treatment — even with AKI — and is the high-yield "exception" to the rule of avoiding ACEi in AKI.

Thrombotic microangiopathies mimicking malignant HTN retinopathy:

Vasculitides:

Infectious:

Hematologic:

Endocrine/metabolic:

Toxic/drug-induced:

Neurologic mimics:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Two-drug oral antihypertensive regimen (single-pill combo preferred): e.g., amlodipine + ACEi/ARB, or ACEi/ARB + chlorthalidone; add third agent (often chlorthalidone if not yet on diuretic) if BP still >130/80 at follow-up

— Statin: moderate-to-high intensity if ASCVD, diabetes 40–75, LDL ≥190, or 10-yr ASCVD ≥7.5%

— Aspirin only for established ASCVD or carefully selected primary prevention

— SGLT2 inhibitor if diabetic with CKD or albuminuria, or HF

— GLP-1 RA if diabetic with ASCVD or obesity

— Address contributors: stop NSAIDs, decongestants, OCPs, stimulants; addiction medicine referral if cocaine/meth

— Written DASH plan, Na <2 g/day, weight loss target, exercise prescription (150 min/wk moderate), alcohol limits, smoking cessation with varenicline or nicotine replacement + counseling, OSA treatment

— <130/80 for HTN with HMOD, diabetes, CKD, ASCVD, or 10-yr risk ≥10%

— Individualize in frail elderly to avoid harm

— Home BP log: twice daily for 1 week before each visit; teach proper technique

— BMP at 1–2 weeks after ACEi/ARB/diuretic start, then 3–6 months

— UACR annually

— Lipids, A1c per risk profile

— Annual dilated eye exam to track retinopathy regression/progression

— Grade I–III findings often regress within 3–12 months of sustained BP control

— Persistent findings flag inadequate control or coexisting diabetic retinopathy

Step 3 management: At discharge after hypertensive emergency, schedule PCP follow-up within 1 week, ophthalmology within 1–2 weeks, nephrology if AKI/CKD, cardiology if HF/ACS — explicit follow-up appointments reduce 30-day readmission.

Discharge medication bundle after hypertensive emergency with retinopathy:

Lifestyle prescription:

Long-term BP target:

Monitoring schedule:

Reverse engineering retinopathy:

Follow-Up, Monitoring Parameters, and Patient Counseling

— Hypertensive emergency discharge: PCP in 1 week, then 2–4 weeks until BP at goal, then every 3 months

— New stage 2 HTN with retinopathy: 2–4 weeks for titration until controlled, then every 3–6 months

— Stable controlled HTN: every 6 months with home BP logs

— Annual: dilated eye exam, lipid panel, UACR, BMP; A1c if diabetic; cardiovascular reassessment

— Validated upper-arm cuff, correct size (bladder covers 80% of arm circumference)

— Seated 5 min rest, feet flat, back supported, arm at heart level, no talking

— Two readings 1 min apart, morning and evening, for 7 days before each appointment; discard first day; average the rest

— Goal home BP <130/80

— Medication adherence and side effects; what to do if a dose is missed (don't double)

— Recognize symptoms requiring urgent care: severe headache, chest pain, vision changes, focal weakness, severe dyspnea

— Avoid OTC NSAIDs and decongestants; show label-reading

— Track sodium, weight, alcohol

— Cardiac rehab if recent ACS or HF

— Dietitian referral

— Health-coach or pharmacist-led HTN management programs improve control rates

— Smoking cessation, alcohol reduction, OSA adherence (CPAP usage logs)

— Screen for depression (PHQ-9) — worsens adherence

— Address health literacy, cost (use $4 generics, 90-day fills, single-pill combos)

— Address food insecurity (DASH diet is expensive)

— Most grade I–III findings reverse with sustained BP control

— Grade IV with optic atrophy may have permanent vision deficit — set expectations

Board pearl: Pharmacist- and nurse-led HTN follow-up clinics with protocolized titration and home BP transmission achieve significantly higher control rates than physician-only visits — favored in value-based care models.

Visit cadence:

Home BP monitoring technique (counsel explicitly):

Self-management education:

Behavioral and rehab:

Psychosocial and adherence:

Communicating prognosis:

Ethical, Legal, and Patient Safety Considerations

— Patients with grade IV retinopathy and significant vision loss may not meet state visual acuity/field standards for driving

— Counsel and document; some states require physician reporting of impaired drivers (e.g., California, Oregon, Pennsylvania, Nevada, New Jersey) — know your state law

— Provide written instructions and alternative transport resources

— Hypertensive encephalopathy may transiently impair capacity — assess capacity at each decision point; use surrogate decision-maker per state hierarchy if incapacitated

— Eclampsia: pregnant patient with altered mental status — treat emergently under emergency exception; involve family and OB ethics if delivery decisions are contested

— Hypertensive emergency discharge without scheduled follow-up is a major 30-day readmission and stroke risk factor

— Use teach-back for new medication regimens; reconcile against home meds

— Ensure eye exam appointment is made before discharge, not just recommended

— Send discharge summary to PCP within 48 hours; flag medication changes and pending studies

— Black, Hispanic, and low-income patients have higher rates of severe and malignant retinopathy

— Address structural barriers: insurance coverage, pharmacy access, food environment, transportation; document social determinants

— Suspected stimulant or cocaine use precipitating HTN crisis — addiction medicine referral; reporting not mandatory unless impaired driving or child endangerment

— Suspected intimate partner violence (stress-related uncontrolled HTN, missed appointments) — screen and offer resources; report only if state mandates or imminent danger

— Counsel about teratogenicity of ACEi/ARB; document contraception plan in reproductive-age women on these drugs

— Postpartum patients with prior preeclampsia: counsel on lifetime CV risk doubling — secondary prevention is ethically and clinically obligatory

— Smart-pump protocols and double-check for IV antihypertensives — nitroprusside dose errors are sentinel events

— Arterial line for accurate BP during titration prevents over-correction

Step 3 management: A 78-year-old with grade IV retinopathy, vision 20/200, and persistent driving — document counseling, notify state DMV per local law, involve family and social work — patient safety overrides autonomy when public risk is significant.

Driving and visual function:

Informed consent edge cases:

Transitions of care risks (Step 3 favorite):

Health disparities and equity:

Mandatory reporting and public health:

Pregnancy and reproductive rights:

Quality and safety:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: A previously well 28-year-old with BP 220/130, scotomata, macular star exudates, and disc edema — think secondary HTN: pheochromocytoma, renovascular disease, primary aldosteronism, or cocaine — always pursue the workup.

AV nicking = chronic HTN, grade II Keith-Wagener-Barker

Copper wiring (orange-brown light reflex) → silver wiring (white reflex) = progressive arteriosclerosis

Cotton-wool spots = nerve fiber layer infarcts; also seen in diabetes, HIV, anemia, lupus, leukemia

Flame hemorrhages = nerve fiber layer (superficial); dot-blot hemorrhages = deeper retinal layers (diabetes)

Hard exudates in macular star pattern = leakage of lipid; classic for severe HTN

Roth spots (white-centered hemorrhages) = endocarditis, leukemia, anemia, collagen vascular disease — not specific to endocarditis

Papilledema with severe HTN = grade IV / malignant HTN = hypertensive emergency

Elschnig spots, Siegrist streaks = hypertensive choroidopathy (young patients, acute severe HTN, eclampsia, pheo)

"Blood and thunder" fundus = CRVO

Cherry-red spot = CRAO (also Tay-Sachs, Niemann-Pick — but those are pediatric metabolic)

Pizza-pie retinopathy = CMV in advanced HIV

Boxcarring of vessels = retinal artery occlusion

Tilted disc, peripapillary atrophy = myopia, not HTN

MAP reduction ≤25% in first hour in hypertensive emergency (except aortic dissection, where target is faster)

Aortic dissection target: SBP <120, HR <60 within 20 min — beta-blocker before vasodilator to prevent reflex tachycardia

Pheo: alpha-block (phenoxybenzamine) days before beta-block; never beta-block alone

Cocaine HTN: benzos first, then phentolamine or CCB; avoid pure beta-blockers

Eclampsia: magnesium for seizures, labetalol/hydralazine/nifedipine for BP, delivery

Scleroderma renal crisis: ACEi (captopril) — exception to AKI rule

Resistant HTN fourth-drug: spironolactone (PATHWAY-2)

First-line in Black patients without CKD: CCB or thiazide

First-line with CKD + proteinuria: ACEi/ARB

Pregnancy first-line: labetalol, nifedipine ER, methyldopa, hydralazine

Drugs causing HTN: NSAIDs, decongestants, OCPs, stimulants, EPO, VEGFi, calcineurin inhibitors, glucocorticoids, MAOI+tyramine

Non-dipping nocturnal BP = poor prognosis; consider bedtime dosing

Board Question Stem Patterns

Key distinction: When the stem gives a specific retinal finding plus BP value, the trick is usually identifying the underlying cause (pheo, eclampsia, scleroderma, cocaine) rather than the retinopathy grade — drug choice depends on the cause.

Stem 1 — Routine office finding: 55-year-old with BP 156/96 referred from optometrist for "AV nicking and arteriolar narrowing." Best next step? → confirm HTN with HBPM/ABPM, assess HMOD (ECG, UACR, BMP, lipids), initiate two-drug therapy if stage 2 confirmed; target <130/80.

Stem 2 — Hypertensive emergency: 62-year-old with BP 230/132, headache, blurred vision. Fundoscopy shows bilateral disc edema, flame hemorrhages, cotton-wool spots, macular exudates. Next step? → ICU admission, IV labetalol or nicardipine, arterial line; lower MAP ≤25% in first hour. Not nifedipine SL (overshoot).

Stem 3 — Pheochromocytoma trap: 30-year-old with episodic palpitations, sweating, headaches; BP 210/120 with cotton-wool spots and exudates. Patient given metoprolol → BP rises further. Why? Unopposed alpha vasoconstriction. Correct sequence: phenoxybenzamine first, then beta-blocker, then surgical resection.

Stem 4 — Preeclampsia: 32-week pregnant woman, BP 168/110, headache, visual scotomata, 3+ proteinuria, plt 80k. Fundus: cotton-wool spots. Treatment? IV labetalol or hydralazine + magnesium sulfate + delivery planning. Avoid ACEi/ARB/nitroprusside.

Stem 5 — Scleroderma renal crisis: patient with scleroderma develops BP 200/120, AKI, schistocytes, retinopathy. First-line drug? Captopril (ACEi) — despite AKI.

Stem 6 — Cocaine HTN: 28-year-old after cocaine binge, BP 210/130, agitated, with flame hemorrhages. Best initial drugs? Benzodiazepines + phentolamine or nicardipine. Avoid metoprolol.

Stem 7 — Pediatric secondary HTN: 8-year-old with BP 150/95, fundus shows AV nicking. Next step? Secondary HTN workup: renal US Doppler, plasma renin, metanephrines, echo (coarctation).

Stem 8 — Aortic dissection complicated by HTN: tearing chest pain, BP 200/110, widened mediastinum. First drug? Esmolol (beta-blocker) before nitroprusside or nicardipine to prevent reflex tachycardia and shear stress.

Stem 9 — Differential of disc edema: young obese woman with bilateral disc edema, normal BP, headache worse supine. Diagnosis? Idiopathic intracranial hypertension — not hypertensive retinopathy. MRI/MRV + LP.

One-Line Recap

— Grade I–II = chronic HTN signature (arteriolar narrowing, AV nicking, copper/silver wiring); confirms HMOD and tightens BP target.

— Grade III = moderate retinopathy (flame hemorrhages, cotton-wool spots, hard exudates, macular star); urgent outpatient escalation, two-drug therapy, ophthalmology in 1–2 weeks.

— Grade IV = malignant HTN / hypertensive emergency (papilledema); admit to ICU, IV labetalol or nicardipine, lower MAP ≤25% in the first hour, then to 160/100 over 2–6 hours, then normalize over 24–48 hours; treat the precipitant (pheo → phentolamine then alpha-block; eclampsia → magnesium + labetalol/hydralazine + delivery; cocaine → benzos + phentolamine; scleroderma renal crisis → captopril; dissection → esmolol first).

— Always pursue secondary HTN workup in young patients, abrupt onset, resistant HTN, or retinopathy disproportionate to BP — renovascular, aldosteronism, pheo, Cushing, OSA, coarctation.

Board pearl: The single most important Step 3 teaching point is that retinopathy = HMOD = stricter target (<130/80) + urgency tier matching grade, and that controlled, not precipitous, BP lowering prevents the very ischemic strokes and optic infarcts you are trying to avoid.

Bottom line: Hypertensive retinopathy is a clinical biomarker of HTN-mediated end-organ damage — graded by Keith-Wagener-Barker (I: arteriolar narrowing; II: AV nicking; III: hemorrhages/cotton-wool spots/exudates; IV: papilledema = hypertensive emergency) — that reclassifies the patient to a stricter <130/80 BP target and, when papilledema is present, mandates ICU-level IV antihypertensives with controlled MAP reduction of ≤25% in the first hour.

Rapid recap bullets: